Search Results

< Back Hookworm Therapy: Advancing Type 2 Diabetes treatment? New research looks at the potential of hookworms to offer improvements in insulin resistance among volunteers at risk of type 2 diabetes. Nature Communications , in its summer edition of 2023, brought forth ground-breaking research that could potentially revolutionise the treatment and prevention of metabolic diseases , particularly type 2 diabetes. Researchers utilised live hookworm infections which resulted in significant improvements in insulin resistance among volunteers at risk of type 2 diabetes, igniting enthusiasm for a larger-scale international trial involving hookworm therapy. When hookworms come to mind, the typical association is tiny parasitic worms that can cause illness. Nevertheless, since the 70s scientists have been investigating helminth (worm) infections as a possible strategy to address a range of ailments encompassing allergies, autoimmune diseases, and now, metabolic conditions. The theory behind this approach is rooted in the hygiene hypothesis, which suggests that the decline in parasitic worm infections, due to improved sanitation, may have contributed to rising rates of metabolic and autoimmune diseases. Metabolic Diseases and Type 2 Diabetes: A Growing Concern Metabolic diseases encompass a range of health conditions often characterised by inflammatory immune responses. An example of a metabolic disease is type 2 diabetes—a chronic ailment characterised by insulin resistance and elevated blood sugar levels. The prevalence of type 2 diabetes is increasing globally, with over half a billion adults already diagnosed. In the UK, more than 4.9 million individuals are presently diagnosed with diabetes, and the vast majority of them (around 90%) have type 2 diabetes. This growing health concern calls for innovative preventative approaches to reduce the burden on individuals and healthcare systems. The Hygiene Hypothesis: Why hookworms? In regions where parasitic worms are endemic, the prevalence of type 2 diabetes and other metabolic diseases tends to be lower. However, the introduction of deworming programs in these areas has been followed by an increase in metabolic disease rates. Interestingly, when people are ‘dewormed’, their insulin resistance tends to surge . Insulin resistance is a critical factor in regulating blood sugar levels and plays a role in the development of metabolic issues like type 2 diabetes and cardiovascular disease. However, it is crucial to acknowledge that the rise in diabetes after interventions in these areas may result from lifestyle changes, such as a reduction in exercise or increased fast food consumption. Figure 1: Effect of deworming on frequency of metabolic disease Hookworms and Immune Response: The connection Low-grade, systemic inflammation is a well-established contributor to insulin resistance. A biased type-1 immune response can worsen insulin resistance by targeting components in the insulin-signalling pathway. Therefore, to combat insulin resistance in metabolic diseases, maintaining a balanced inflammatory response by favouring a type 2 or regulatory immune response, is essential to halt the detrimental cascade of inflammation. Helminth infections are associated with type 2 immune responses and alterations to the gut microbiome . Studies involving worm infections in animal models have demonstrated improvements in metabolic parameters, type 2 immune responses, and changes in the gut microbiome, but no human trials have been conducted. Until now. The study: A Pioneering Human Trial The world-first human trial conducted at James Cook University involved experimental hookworm infection in 40 participants, all at risk for type 2 diabetes and cardiovascular disease. In a two-year, randomised, double-blinded clinical trial, 27 participants were infected with either 20 or 40 Necator americanus larvae, while 13 received placebos. In order to induce a placebo effect, or in this instance, a nocebo effect, researchers employed chilli pepper sauce to simulate the sensation of hookworm larvae penetrating the arm. This approach is commonly referred to as a sham intervention, as it led the control group participants to believe that they had also been exposed to hookworms. The primary aim of this phase 1 study was to confirm the safety of this innovative therapy. The study showed that adverse events were more frequent in the hookworm-treated group, mainly manifesting as gastrointestinal symptoms, but completion rates were comparable to the placebo group. Remarkably, the study found that low hookworm infection was associated with improvements in insulin resistance and fasting blood glucose, with all but one participant opting to keep their hookworms after the trial. Notably, the consistent monitoring of dietary and physical activity habits did not reveal any discernible changes between the infected and control groups. Figure 2: Summary of study findings Promising Results: The Path Ahead The research offers a promising insight into the potential of live hookworms for improving metabolic health. While these results are encouraging, it is essential to recognize that this is just the beginning. Larger clinical trials are needed to determine the optimal dosage of hookworms and to clarify the mechanisms behind their positive effects on metabolic health. Researchers hope to uncover the specific molecules released by hookworms that suppress inflammation and improve metabolism. In the quest to harness the power of hookworms, scientists are exploring protein-based treatments that mimic the effects of live worms, potentially providing a more palatable and controlled alternative for patients. However, many questions remain unanswered, including how hookworms precisely impact human metabolism, whether through immune system manipulation and/or weight loss. Closing Thoughts: Are we hooked? Before rushing to embrace hookworms as a solution for metabolic and autoimmune diseases, it's vital to remember that these results are preliminary and come with some caveats. Individual responses may vary depending on the dosage and follow-up protocols. This research paves the way for future investigations, offering new hope in the fight against type 2 diabetes and metabolic diseases. As the scientific community delves deeper into the potential of hookworms, we may unlock new possibilities for improved metabolic health and overall well-being. Author Petra Gudelj , freelance contributor Previous Next

Novartis' Phase III study of intrathecal onasemnogene abeparvovec for spinal muscular atrophy (SMA) successfully met its primary endpoint, showing significant motor function improvements. < Back Novartis' Intrathecal Onasemnogene Abeparvovec Phase III Study Meets Primary Endpoint Novartis' Phase III study of intrathecal onasemnogene abeparvovec for spinal muscular atrophy (SMA) successfully met its primary endpoint, showing significant motor function improvements. Novartis announced today that its Phase III study of intrathecal onasemnogene abeparvovec (brand name: Zolgensma) has successfully met its primary endpoint, showing significant clinical improvements in children and young adults with spinal muscular atrophy (SMA). The data from this global trial marks a promising step forward in the treatment of SMA, a rare, genetic neurodegenerative disease that leads to muscle weakness and, in severe cases, early death. The trial evaluated the efficacy and safety of onasemnogene abeparvovec delivered via intrathecal (directly into the spinal fluid) injection, a delivery method designed to target the central nervous system more effectively. The primary endpoint of the study was the improvement in motor function, as measured by the Hammersmith Functional Motor Scale Expanded (HFMSE), a widely used assessment for SMA. The results showed statistically significant improvements in motor function for children and young adults treated with the therapy compared to baseline measures. SMA, caused by mutations in the SMN1 gene, leads to a progressive loss of motor neurons, significantly impairing muscle strength and movement. Prior to the approval of Zolgensma in its current form (IV administration), treatment options were limited, and the disease often led to irreversible damage and early death, particularly in the most severe cases, such as SMA Type 1. This intrathecal formulation of onasemnogene abeparvovec is designed to address the needs of older patients who may not have been eligible for intravenous treatment. By offering a new, potentially more effective delivery method for the therapy, Novartis aims to broaden the impact of Zolgensma, especially in those with later-onset forms of SMA who still experience significant functional decline. "This milestone represents a significant advancement in SMA care and brings hope to patients who have been previously underserved by available treatments," said Nimisha Nair, Global Head of Neurosciences at Novartis. "We are excited by the potential of intrathecal Zolgensma to offer a meaningful treatment option for a broader range of children and young adults with SMA." The study also assessed the safety profile of the intrathecal formulation. According to Novartis, the treatment was generally well-tolerated, with no new safety concerns identified compared to the previously approved intravenous formulation. The company is now preparing to submit these findings to regulatory authorities worldwide, with the hope of expanding the approved indications for onasemnogene abeparvovec to include intrathecal administration. If approved, this new method of delivery could provide a significant therapeutic option for SMA patients, potentially improving quality of life and delaying disease progression. About Onasemnogene Abeparvovec (Zolgensma) Zolgensma is a gene therapy that works by replacing the missing or nonfunctional SMN1 gene with a fully functional copy, aiming to address the underlying cause of SMA. It was initially approved by the U.S. FDA in 2019 for use in children under 2 years of age and has since been shown to improve motor function in infants with SMA. The new intrathecal formulation expands its potential use to a broader age range. The results from this Phase III study come as a beacon of hope for the SMA community, where early intervention remains crucial. With SMA affecting approximately 1 in 10,000 live births globally, the treatment landscape has evolved rapidly, and Novartis is positioning Zolgensma as a cornerstone of therapy for the disease. Author BioFocus Newsroom Previous Next

< Back World Health Summit 11th - 13th October, 2026 Berlin, Germany From Crisis to Resilience: Innovating for Health ! Widget Didn’t Load Check your internet and refresh this page. If that doesn’t work, contact us. Previous Next

Bayer Pharmaceuticals implements leadership streamlining amid restructuring efforts. < Back Bayer Pharmaceuticals Shakes Up Leadership Structure Bayer Pharmaceuticals implements leadership streamlining amid restructuring efforts. Bayer Pharmaceuticals , a key player in the pharmaceutical industry, has recently announced significant leadership restructuring aimed at streamlining operations and enhancing efficiency. This strategic move comes amidst ongoing efforts to optimize organizational structure and adapt to evolving market dynamics. The restructuring initiative involves a reshuffling of executive positions within Bayer Pharmaceuticals, with the aim of fostering greater collaboration and alignment across various departments. By consolidating leadership roles, the company seeks to facilitate faster decision-making processes and improve overall agility in responding to market demands. This development follows Bayer's earlier announcement of plans to restructure its pharmaceutical division, focusing on key therapeutic areas and reallocating resources to support innovation and growth. The streamlined leadership team is expected to play a pivotal role in driving these strategic objectives forward. The restructuring efforts underscore Bayer's commitment to remaining competitive in the rapidly evolving pharmaceutical landscape. By simplifying its organizational hierarchy and optimizing leadership functions, the company aims to enhance operational efficiency and accelerate the pace of innovation. In a statement regarding the leadership streamlining, Bayer Pharmaceuticals emphasized its dedication to delivering impactful healthcare solutions and improving patient outcomes. The company remains focused on advancing its pipeline of innovative therapies and strengthening its position as a leader in the pharmaceutical industry. As Bayer Pharmaceuticals continues to navigate the challenges and opportunities presented by the healthcare market, the streamlined leadership structure is poised to facilitate greater agility and effectiveness in pursuing strategic goals. Through ongoing innovation and operational excellence, Bayer remains committed to driving positive change and making meaningful contributions to global healthcare. Author BioFocus Newsroom Previous Next

Vertex Pharmaceuticals has announced a major milestone in the treatment of cystic fibrosis (CF) with the U.S. FDA approval of ALYFTREK™, a once-daily triple combination therapy. < Back Vertex Announces FDA Approval of ALYFTREK™ for Cystic Fibrosis Treatment Vertex Pharmaceuticals has announced a major milestone in the treatment of cystic fibrosis (CF) with the U.S. FDA approval of ALYFTREK™, a once-daily triple combination therapy. Alyftrek builds on the success of previous cystic fibrosis transmembrane conductance regulator (CFTR) modulators, providing a novel option for patients ages six and older with at least one responsive CFTR mutation, including 31 mutations previously untreatable by existing modulators. Achieving FDA approval here is a testament to Vertex’s commitment to addressing the underlying causes of CF and expanding treatment access. A New Standard in CF Treatment For the first time, patients have access to a CFTR modulator with once-daily dosing—a feature addressing a significant unmet need for easier treatment regimens. This advancement could improve medication adherence and overall quality of life for individuals managing the daily demands of CF. The therapy also expands the reach of CFTR modulation, enabling treatment for approximately 150 patients in the U.S. who previously lacked viable options. In clinical trials, Alyftrek demonstrated non-inferiority to Trikafta in improving lung function (measured as ppFEV1) and showed statistically significant reductions in sweat chloride levels, a biomarker of CF disease severity. These findings underscore Alyftrek’s potential to set a new benchmark for effective CF care. Supporting the Broader CF Community With over 92,000 people globally affected by CF, the need for innovative treatments remains urgent. CF is a progressive, multi-organ disease caused by defective or missing CFTR proteins due to genetic mutations. This dysfunction leads to thick, sticky mucus in the lungs and other organs, driving chronic infections, progressive damage, and premature death. Vertex has steadily worked to mitigate these impacts, with its CFTR modulators now treating two-thirds of eligible CF patients worldwide. Alyftrek’s approval follows the most comprehensive Phase 3 trial program in CF to date, spanning more than 1,000 patients across over 20 countries. The results reinforce Vertex’s leadership in developing therapies that not only improve lung function but also address systemic biomarkers like sweat chloride. The therapy’s safety profile was consistent with other CFTR modulators, making it a well-tolerated option for a wide range of patients. The Path Ahead While Alyftrek’s FDA approval is a milestone for the U.S., Vertex’s ambition extends globally. Regulatory submissions are underway in Europe, the U.K., Canada, and other regions, reflecting a commitment to delivering life-changing therapies to patients worldwide. The introduction of Alyftrek’s reflects the progress made in CF research, yet challenges remain. Median life expectancy for CF patients still hovers in the 30s, underscoring the ongoing need for innovation. Alyftrek’s offers hope not only through its expanded reach but also through its potential to ease treatment burdens, allowing patients to focus more on their lives and less on their disease. Alyftrek’s enters the CF market at a list price of $370,269 per year, a 7% premium over Trikafta’s annual cost. While its clinical benefits and more convenient dosing are expected to drive patient transitions, analysts predict a slower adoption curve compared to Trikafta’s groundbreaking launch in 2019. Early adopters are likely to include patients experiencing suboptimal outcomes with Trikafta, estimated to comprise 20-30% of current users. While Alyftrek’s approval underscores Vertex’s dominance in CF therapeutics—a franchise projected to exceed $10 billion in annual sales—the company faces investor scrutiny over its pain candidate, suzetrigine . This nonaddictive alternative to opioids has blockbuster potential, but disappointing Phase 2 data has cast doubt on its near-term prospects, overshadowing Alyftrek’s launch. Conclusion Vertex’s approval of Alyftrek highlights the company’s dedication to transforming CF care. With expanded mutation coverage, improved dosing convenience, and strong clinical outcomes, Alyftrek is poised to enhance the lives of thousands of patients. As Vertex continues to lead in CF innovation, therapies like Alyftrek signal a brighter future for the CF community. Author BioFocus Newsroom Previous Next

< Back World Health Summit 11th - 13th October, 2026 Berlin, Germany From Crisis to Resilience: Innovating for Health ! Widget Didn’t Load Check your internet and refresh this page. If that doesn’t work, contact us. Previous Next

< Back World Health Summit 11th - 13th October, 2026 Berlin, Germany From Crisis to Resilience: Innovating for Health ! Widget Didn’t Load Check your internet and refresh this page. If that doesn’t work, contact us. Previous Next

​​REDEFINE 2 Phase 3 trial showed CagriSema led to a 15.7% weight loss in adults with obesity and type 2 diabetes, but the results fell short of expectations, causing a decline in the company's stock value. < Back Novo Nordisk Announces Promising Results for CagriSema but Stocks Tell Different Story REDEFINE 2 Phase 3 trial showed CagriSema led to a 15.7% weight loss in adults with obesity and type 2 diabetes, but the results fell short of expectations, causing a decline in the company's stock value. Novo Nordisk has announced what they claim to be impressive results from its REDEFINE 2 Phase 3 clinical trial, showing that CagriSema, a once-weekly subcutaneous treatment, delivers superior weight loss for adults with obesity or overweight and type 2 diabetes. The trial, which involved 1,206 participants, demonstrated that CagriSema resulted in a significant weight loss of 15.7% after 68 weeks, compared to just 3.1% with a placebo. Novo Nordisk's recent REDEFINE 2 Phase 3 trial evaluated CagriSema—a combination of cagrilintide and semaglutide—for weight loss in patients with obesity or overweight and type 2 diabetes. After 68 weeks, participants experienced an average weight loss of 15.7%, surpassing the 3.1% loss observed in the placebo group. However, this outcome fell short of both the anticipated 25% weight loss and the 22.7% reduction reported in a previous trial, leading to a significant decline in Novo Nordisk's stock value. The trial involved 1,206 participants, with 61.9% achieving the highest dose of CagriSema. While the treatment was generally well-tolerated, with mild to moderate gastrointestinal side effects diminishing over time, investors expressed disappointment over the results, especially given the competitive landscape with drugs like Eli Lilly's Mounjaro. Despite these challenges, Novo Nordisk remains committed to advancing CagriSema, with plans to seek regulatory approval in early 2026. The company continues to conduct additional trials to further assess the drug's efficacy and potential in the market. Author BioFocus Newsroom Previous Next

Tinlarebant becomes the first therapy to show clinical benefit in a pivotal global trial, reducing retinal lesion growth by 36% and paving the way for a planned FDA filing in 2026. < Back Belite Bio Announces Landmark Phase 3 Success for Stargardt Disease Tinlarebant becomes the first therapy to show clinical benefit in a pivotal global trial, reducing retinal lesion growth by 36% and paving the way for a planned FDA filing in 2026. In what experts are calling a “historic breakthrough” for inherited eye diseases, Belite Bio today reported positive topline results from its global Phase 3 DRAGON trial of Tinlarebant, the first therapy to show clinical benefit for Stargardt disease in a pivotal study. Stargardt disease, a rare genetic condition that causes progressive vision loss, often beginning in youth, currently has no approved treatment. The condition affects an estimated 50,000 people in the United States. Belite Bio’s DRAGON trial enrolled 104 adolescents with Stargardt disease type 1 (STGD1) across multiple international centers. According to the company, Tinlarebant met its primary endpoint with a statistically significant 36% reduction in the growth rate of retinal lesions compared with placebo (p=0.0033), marking the first time any therapeutic candidate has achieved efficacy in a global Phase 3 trial for STGD1. A post-hoc analysis using an alternate statistical model showed consistent results, with significance strengthened to p<0.0001. “This marks a pivotal moment for families affected by Stargardt disease,” said Dr. Tom Lin, Chairman and CEO of Belite Bio. “Tinlarebant not only slowed retinal degeneration, but did so as an oral therapy, something never before demonstrated in a retinal degenerative disease.” Investigators reported that Tinlarebant also achieved statistically significant lesion-reduction effects in both eyes for the primary and key secondary endpoints. Visual acuity remained largely stable across both treatment and placebo groups, a pattern consistent with the condition’s natural history over 24 months. Safety data were also encouraging. The company said Tinlarebant was generally well tolerated, with only four treatment-related discontinuations and mainly mild ocular side effects such as xanthopsia and delayed dark adaptation. Headaches were the most common non-ocular treatment-related adverse event. Leading ophthalmologists who participated in the study emphasized the magnitude of the findings. “Seeing well-controlled Phase 3 data with such a clear slowing of lesion growth is deeply encouraging,” said Professor Michel Michaelides of Moorfields Eye Hospital in London. “It suggests we may finally be nearing an approved treatment option for this devastating disease.” Dr. Quan Dong Nguyen of Stanford University added that slowing lesion progression could eventually translate into preserved visual function: “It is remarkable to recognize that with these robust results, we may soon have the first available therapy for Stargardt disease.” Tinlarebant works by reducing levels of retinol-binding protein 4 (RBP4), thereby limiting the retinal accumulation of toxic vitamin A by-products implicated in STGD1 and other degenerative conditions. The trial confirmed that the 5 mg dose reduced RBP4 by roughly 80% during treatment. Belite Bio plans to submit a New Drug Application (NDA) to the U.S. Food and Drug Administration in the first half of 2026. Tinlarebant has already received multiple regulatory designations, including Breakthrough Therapy and Orphan Drug status in the U.S., Europe, and Japan. The company will discuss the Phase 3 results during a webcast today at 8:00 a.m. ET. If approved, Tinlarebant would become the first therapy for Stargardt disease Author BioFocus Newsroom Previous Next

While VE202 misses efficacy endpoint, strong safety profile underscores potential of microbiome-based therapies; company doubles down on Phase 3 trial in recurrent C. difficile. < Back Vedanta’s Live Bacteria Cocktail Fails Phase 2 Ulcerative Colitis Trial While VE202 misses efficacy endpoint, strong safety profile underscores potential of microbiome-based therapies; company doubles down on Phase 3 trial in recurrent C. difficile. Vedanta Biosciences, a clinical-stage biopharmaceutical company pioneering oral microbiome-based therapies, today announced that its investigational candidate VE202 did not meet the primary efficacy endpoint in the Phase 2 COLLECTiVE202 study for mild-to-moderate ulcerative colitis (UC). Despite the outcome, the treatment was well tolerated, with no reports of treatment-related serious adverse events, reinforcing the safety of Vedanta’s microbiome consortia platform. COLLECTiVE202 enrolled 114 UC patients across the U.S., Europe, and Australia, testing VE202 as an add-on to stable background therapy. Although endoscopic response rates did not differ significantly from placebo, the company emphasized the study’s value in advancing scientific understanding of the microbiome’s role in inflammatory bowel disease (IBD). “We’re disappointed VE202 did not achieve its efficacy goals, but we remain committed to unlocking the potential of microbiome-based treatments for IBD,” said Dr. Bernat Olle, CEO of Vedanta Biosciences. “The gut microbiome remains a largely untapped avenue in this disease area, and every well-executed study brings us closer to meaningful breakthroughs. We look forward to sharing deeper insights from COLLECTiVE202 at upcoming scientific meetings.” Strategic Focus Remains on VE303 With the VE202 trial now complete, Vedanta is sharpening its focus on its lead program, VE303, currently in a global Phase 3 registrational trial (RESTORATiVE303) for the prevention of recurrent Clostridioides difficile infection (rCDI). Backed by robust Phase 2 data, VE303 has demonstrated best-in-class potential, achieving a 30.5% absolute risk reduction in recurrence and over 80% reduction in the odds of a CDI recurrence compared to placebo. “Our priority now is executing on the promise of VE303, which has the potential to become the first FDA-approved Live Biotherapeutic Product,” said Dr. Olle. “There is a significant unmet need in recurrent C. difficile, and our platform is uniquely positioned to deliver a durable, defined, and scalable therapeutic solution.” Pipeline Progress Continues Vedanta is also advancing VE707, a preclinical program designed to prevent infections caused by multidrug-resistant organisms (MDROs) in vulnerable populations such as oncology and transplant patients. An IND filing is planned for the first half of 2026. Despite the VE202 result, Vedanta remains a leader in the development of defined bacterial consortia therapeutics, supported by one of the industry’s most advanced product engines, including proprietary bacterial libraries, scalable manufacturing infrastructure, and deep expertise in consortium design. Detailed analyses from COLLECTiVE202, including immunological, histological, and colonization findings, will be presented at scientific conferences later this year. Author BioFocus Newsroom Previous Next

The BioFocus Editorial Team recap key developments from 2024 and highlight some of the most promising clinical trials and emerging therapies to keep an eye on. < Back 2025: A Year of Promise in Pharma and Biotech — Key Trials and Drug Candidates to Watch The BioFocus Editorial Team recap key developments from 2024 and highlight some of the most promising clinical trials and emerging therapies to keep an eye on. As the new year begins, the life sciences sector is buzzing with anticipation about the clinical trials and drug candidates that could reshape the landscape of medicine in 2025. With advancements in technology, new biologics, and novel drug delivery systems, 2025 promises to be a year of breakthrough discoveries. In this article, we’ll highlight some of the most promising clinical trials and emerging therapies to keep an eye on, as well as recap some of the key developments from 2024 that set the stage for what’s to come. Key Drug Development Advancements in 2024 Before we look ahead to 2025, let’s first acknowledge some of the landmark moments in drug development from 2024. This year saw substantial progress in several therapeutic areas, including oncology, neurology, and gene therapy: mRNA Therapeutics Beyond COVID-19 : Following the success of mRNA COVID-19 vaccines, 2024 marked a pivotal year for mRNA technology, with several candidates entering late-stage trials for infectious diseases like flu and RSV (Respiratory Syncytial Virus). Pfizer and Moderna are leading the charge in developing mRNA vaccines for a variety of conditions, including cancer, autoimmune diseases, and rare genetic disorders. Gene Editing Advancements : CRISPR and other gene-editing technologies gained significant traction in 2024, with companies like CRISPR Therapeutics and Editas Medicine advancing clinical trials targeting genetic disorders such as sickle cell disease and beta-thalassemia. Early results have shown promise in permanently correcting gene mutations with minimal side effects. Immuno-Oncology Breakthroughs : The immuno-oncology space continued to evolve, with multiple trials showing significant progress in treating cancers that were once considered resistant to immune therapies. The approval of Roche’s Vabysmo and early results from Bristol-Myers Squibb's LAG-3 inhibitor in melanoma and other cancers have raised hopes for novel immune checkpoint inhibitors. Neurodegenerative Disease Innovation : In Alzheimer's and Parkinson’s disease, 2024 saw promising data from Biogen’s Leqembi (lecanemab) and Eli Lilly’s Donanemab . These therapies represent a step forward in targeting amyloid plaques, though the debate over efficacy and safety continues to shape the regulatory landscape. Top Clinical Trials and Drug Candidates to Watch in 2025 As we look forward to 2025, the industry is turning its attention to several promising drug candidates and clinical trials that could change the way we treat a wide range of diseases. Below are the trials and candidates we’re most excited about: 1. AstraZeneca's Enhertu (Trastuzumab Deruxtecan) in HER2-Low Breast Cancer AstraZeneca's HER2-targeted antibody-drug conjugate (ADC), Enhertu , has already shown remarkable efficacy in HER2-positive breast cancer. But in 2025, the focus will shift to HER2-low breast cancer, which represents a significant portion of breast cancer patients. Phase III trials are already underway, and data from these studies could revolutionize treatment for a broader group of patients, potentially establishing Enhertu as a cornerstone of breast cancer therapy. 2. Novartis’s Kymriah (Tisagenlecleucel) in Solid Tumors Kymriah, an FDA-approved CAR T-cell therapy, has already made significant waves in blood cancers like leukemia and lymphoma. However, its extension into solid tumors could be a game changer. Phase II and III trials are testing Kymriah’s efficacy against non-Hodgkin lymphoma, glioblastoma, and other solid malignancies. Success here could make Kymriah a revolutionary tool in treating cancers that have traditionally been much harder to treat with immunotherapy. 3. Vertex Pharmaceuticals’ CRISPR-Based Cystic Fibrosis Treatment 2025 could be the year that CRISPR finally delivers on its promise of curative treatments for genetic diseases. Vertex Pharmaceuticals , in collaboration with CRISPR Therapeutics, is progressing with a trial that uses gene editing to correct the underlying genetic defect in cystic fibrosis (CF). This trial has the potential to not only provide a one-time cure for CF but also to open the door to gene-editing solutions for a host of other genetic disorders. 4. AbbVie’s Rinvoq (Upadacitinib) for Rheumatoid Arthritis AbbVie’s Rinvoq has already established itself as a promising treatment for inflammatory diseases, but in 2025, the focus will be on its use in rheumatoid arthritis (RA) and other autoimmune conditions. The Phase III trials examining Rinvoq’s potential in RA patients who are non-responders to traditional biologics could position it as a leading therapy in the autoimmune disease market, particularly if it can demonstrate a faster onset of action and improved efficacy over older treatments. 5. Sarepta’s Gene Therapy for Duchenne Muscular Dystrophy (DMD) Sarepta’s SRP-9001 , a gene therapy targeting Duchenne muscular dystrophy (DMD), is one of the most anticipated therapies in the gene therapy space. Phase III trials are expected to deliver data in 2025, and early results have already shown promise in helping DMD patients retain muscle function and slow disease progression. If successful, this therapy could offer a transformative treatment option for DMD patients, an area where few effective treatments currently exist. 6. Neurocrine Biosciences’ Ingrezza (Valbenazine) for Tardive Dyskinesia (TD) Neurocrine Biosciences’ Ingrezza has already been a major player in treating tardive dyskinesia, a side effect of antipsychotic medications. However, 2025 will see the expansion of Ingrezza into new indications like Huntington’s disease and Parkinson’s disease -related movement disorders. If clinical trials are successful, this could position Ingrezza as a cornerstone therapy for a broad range of neurodegenerative disorders. 7. Pfizer’s Oral OX40 Agonist for Autoimmune Diseases Pfizer is working on a first-in-class oral OX40 agonist , PF-06831807 , which has shown promise in early trials for autoimmune diseases such as lupus and psoriasis . This candidate works by stimulating the OX40 receptor on T-cells, enhancing the body’s immune system while potentially reducing inflammation. If ongoing trials in 2025 confirm its safety and efficacy, this could be a major breakthrough in autoimmune disease therapy. Looking Ahead: Optimism and Challenges With the potential for several game-changing therapies to enter the market, industry anticipation around 2025 is high. However, it’s important to recognize that with every new therapeutic advance, there are also challenges. Regulatory hurdles, safety concerns, and the need for robust real-world data will play significant roles in determining whether these drug candidates reach the patients who need them. Moreover, issues like pricing, accessibility, and long-term efficacy will remain critical factors in the adoption of new treatments. Political and geopolitical factors will continue to shape drug development and clinical trial approvals this year, with regulatory divergence, trade policies, and international relations playing key roles. Political stability in major markets like the U.S., EU, and China can influence the speed and ease of drug approvals, while tensions between countries—such as trade wars or sanctions—may delay access to critical medicines or disrupt global supply chains. Additionally, political pressure to control drug prices in publicly funded healthcare systems could affect the commercial viability of new therapies. With increasing global interdependence, multinational clinical trials and international collaborations will also be affected by shifting regulations, requiring drug developers to navigate complex, often divergent regulatory landscapes to ensure broader approval and market access. Nevertheless, the sheer breadth of innovation on the horizon means that 2025 could be a banner year for the pharma and biotech industries. Whether it’s harnessing the power of gene editing, revolutionizing cancer treatment, or advancing immunotherapy, the future of medicine looks brighter than ever. At BioFocus, we’re committed to tracking these developments closely, providing our readers with up-to-date insights and analysis on the drugs and trials shaping the future of healthcare. Stay tuned as we continue to monitor the cutting-edge advances in the biotech and pharma worlds throughout the year. Author BioFocus Newsroom Previous Next

Pfizer halts once-daily oral GLP-1 program danuglipron after liver safety concerns, shifting focus to alternative obesity targets including a GIPR antagonist in Phase 2. < Back Pfizer Halts Development of Oral GLP-1 Agonist Danuglipron Amid Liver Safety Signal Pfizer halts once-daily oral GLP-1 program danuglipron after liver safety concerns, shifting focus to alternative obesity targets including a GIPR antagonist in Phase 2. Pfizer Inc. (NYSE: PFE) has discontinued development of its oral GLP-1 receptor agonist, danuglipron (PF-06882961), following a clinical finding of potential drug-induced liver injury during Phase 2 dose-optimization studies. The decision marks a strategic retreat from one of the few oral GLP-1 assets positioned to challenge the current dominance of injectable incretin therapies in the obesity market. Danuglipron, a small-molecule GLP-1R agonist administered once daily, had been in development as an oral alternative to GLP-1 peptide injectables such as semaglutide (Novo Nordisk’s Wegovy) and tirzepatide (Eli Lilly’s Zepbound). Pfizer reported that while the pharmacokinetic and tolerability profiles in its latest once-daily formulation study met key objectives, a single case of elevated liver enzymes consistent with potential drug-induced liver injury prompted an internal risk-benefit reassessment. “Although the formulation achieved desired PK exposure and early indicators of efficacy, we observed an adverse hepatic event that, while reversible upon discontinuation, raised enough concern to halt development,” said Mikael Dolsten, MD, PhD, Chief Scientific Officer and President, Pfizer R&D. This decision follows an earlier discontinuation in 2023 of danuglipron’s twice-daily formulation, which suffered from dose-limiting GI tolerability issues including nausea and vomiting. The once-daily version was expected to mitigate these adverse effects while preserving weight loss efficacy. Implications for GLP-1 Drug Development and Competitive Landscape Pfizer’s exit from danuglipron development underscores the complexities of formulating safe, orally bioavailable GLP-1R agonists. Despite its promising preclinical and early clinical data, danuglipron faced increasing safety scrutiny given the class-wide regulatory sensitivity to hepatotoxicity and long-term tolerability in a chronic disease context. With obesity positioned as a multi-billion-dollar therapeutic area projected to exceed $100B globally by 2030, Pfizer’s withdrawal leaves a narrower field of oral GLP-1 contenders. Eli Lilly’s orforglipron and Viking Therapeutics’ VK2735, among others, continue to progress in clinical development, each aiming to deliver oral or small-molecule alternatives to peptide-based therapies. Market reaction to Pfizer’s move was swift. Shares of Novo Nordisk and Eli Lilly rose modestly on Monday, with investors viewing the decision as a de-risking of their market share in obesity and type 2 diabetes. Meanwhile, Pfizer reaffirmed its commitment to the space through other mechanisms. Strategic Refocus: GIPR Antagonist in the Pipeline While terminating danuglipron, Pfizer highlighted ongoing development of an oral glucose-dependent insulinotropic polypeptide receptor (GIPR) antagonist candidate, currently in Phase 2. GIP modulation is being explored both as monotherapy and in combination with GLP-1 agents for synergistic metabolic effects. “We remain committed to advancing next-generation metabolic therapies and are reallocating our internal resources toward novel mechanisms, including oral GIPR antagonists and other first-in-class approaches,” Dolsten said. Pfizer did not disclose timelines for GIPR candidate readouts but indicated continued focus on cardiometabolic disease as a core strategic priority. The company is expected to provide pipeline updates in upcoming earnings calls and at scientific congresses later this year. Outlook Pfizer’s withdrawal from danuglipron reflects both the regulatory and scientific headwinds facing oral GLP-1 drug development. The hepatic safety signal, even in a single subject, proved incompatible with chronic use in a preventive population — a reminder of the high safety bar required for obesity pharmacotherapies. With major pharma consolidating around either peptide injectables or next-generation dual/triple agonist platforms, the search for safe, effective, and convenient oral agents continues — and remains a highly competitive frontier for innovation. Author BioFocus Newsroom Previous Next